Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

(2022) Sue Ann Costa Clemens et al.   LANCET

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination

(2022) Eddy Pérez-Then et al.   NATURE MEDICINE

A review of the safety and efficacy of current COVID-19 vaccines

(2022) Zehong Huang et al.   Frontiers of Medicine

Potent antibody immunity to SARS‐CoV‐2 variants elicited by a third dose of inactivated vaccine

(2022) Bin Ju et al.   Clinical and Translational Medicine

COVID-19 vaccine trials: The use of active controls and non-inferiority studies

(2021) Thomas R Fleming et al.   Clinical Trials

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

(2021) Mine Durusu Tanriover et al.   LANCET

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

(2021) Alejandro Jara et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients

(2021) Lu Lu et al.   CLINICAL INFECTIOUS DISEASES

Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review

(2021) Thibault Fiolet et al.   CLINICAL MICROBIOLOGY AND INFECTION

COVID-19 vaccine strategies must focus on severe disease and global equity

(2021) Peter B McIntyre et al.   LANCET

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials

(2021) Gang Zeng et al.   LANCET INFECTIOUS DISEASES

China’s COVID vaccines have been crucial — now immunity is waning

(2021) Smriti Mallapaty   NATURE

Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine

(2021) Felipe Melo-González et al.   Frontiers in Immunology

Can a combination of vaccination and face mask wearing contain the COVID‐19 pandemic?

(2021) Harald Brüssow et al.   Microbial Biotechnology

PICK-ing Malaysia’s Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio

(2021) Jing Lian Suah et al.   Vaccines

Development of an Inactivated Vaccine against SARS CoV-2

(2021) Shaikh Terkis Islam Pavel et al.   Vaccines